Phase 2 Liver Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged 18 or older
• People who are generally well enough to carry out daily activities with little or no limitation (as measured by a standard health scale called ECOG, score 0 or 1)
• People who have been diagnosed with liver cancer (HCC) through a tissue sample, where surgery or local treatment to remove or destroy the cancer is not possible
• People whose liver cancer was shown on scans to have grown or spread during or after local treatment, or after treatment with sorafenib or lenvatinib, or who were unable to tolerate or chose not to receive those medicines
• People who have had at least one previous systemic (whole-body) treatment for liver cancer
• People whose treating doctor determines they are suitable for treatment with nivolumab
• People who have at least one area of cancer that can be measured on scans, using a standard method called RECIST v1.1
• People whose liver is still functioning at a level called Child-Pugh class A, confirmed within 7 days before the first dose
• People with no history of a condition called hepatic encephalopathy (confusion or brain problems caused by liver disease)
• People with no significant fluid build-up in the abdomen (ascites) that requires a medical procedure to drain it — fluid visible only on scans but not causing symptoms may still be acceptable (confirm with trial site)
• People with hepatitis B (HBV) infection who have been on antiviral treatment for at least 12 weeks and whose HBV virus levels are confirmed to be below 100 IU/mL within 7 days before the first dose
• People who do not have an active simultaneous infection of both hepatitis B and hepatitis C, or both hepatitis B and hepatitis D
• People with no current or recent problems with drug or alcohol misuse

Who may not be able to join:

• People who have taken a type of cancer medicine called a tyrosine kinase inhibitor within 2 weeks before the first dose
• People who have had bleeding from swollen veins in the oesophagus or stomach within the past 6 months
• People whose liver cancer has grown into the main portal vein, the large vein returning blood to the heart (inferior vena cava), or the heart itself, as seen on scans
• People who have previously had an organ or bone marrow/blood cell transplant
• People who have an active autoimmune disease (where the immune system attacks the body) that has required ongoing medical treatment in the past 2 years
• People who have been diagnosed with an immune system deficiency, or who have been taking steroid medicines or other immune-suppressing medicines within 7 days before the first dose
• People who have had a local liver treatment or major liver surgery within 6 weeks before the first dose
• People who have had minor surgery to the liver or anywhere else in the body within 1 week before the first dose

Important: Always verify eligibility with the trial site directly before applying.